Trials / Completed
CompletedNCT02119104
Prevenar (13v) Infant Drug Use Investigation
Prevenar (13v) Infant Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,087 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 2 Months – 6 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate post marketing use and safety of Prevnar ( 13v) in infants vaccinated for the first time at the age of 2 months, inclusive, to 7 months, exclusive.
Detailed description
The investigation will be conducted using the continuous investigation method, with which a satisfying registration conditions will be continuously registered until the number of contracted cases is reached.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prevenar (13v) | Prevenar (13v) |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2014-04-21
- Last updated
- 2017-06-19
- Results posted
- 2017-06-19
Source: ClinicalTrials.gov record NCT02119104. Inclusion in this directory is not an endorsement.